September 17, 2014—Drug companies that invite health care providers to talk about possible 340B drug diversion or duplicate discounts will often find that their customers are quite open and can either explain any anomalies or will be quick to rectify the matter, an attorney for manufacturers and an industry consultant said at an industry conference in Chicago yesterday.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)